Skip to main content
Profile picture for Alexa Meara MD

Alexa Meara MD

Alexa Meara, MD is a graduate of the Georgetown University School of Medicine (2008). She completed her internal medicine training at East Carolina University (ECU) at Vidant Medical Center (2008-20011), then becoming Chief Resident in Internal Medicine at ECU (2011-2012). She was then recruited as the associate training Program Director for Internal Medicine (2012-2013). She pursued further training in Rheumatology at The Ohio State University from 2013-2015. After completing 2 extra years of fellowship for expanding her research (2015-2017). She is an Assistant Professor of Immunology and Rheumatology at OSU. Currently she maintains a multidisciplinary vasculitis clinic and supervises a longitudinal registry of lupus nephritis and vasculitis patients. Her clinical research is understanding the immune related adverse events second to cancer immunotherapy. Her priority is understanding patients with pre-existing autoimmune disease and subsequent side effects from cancer immunotherapy.

Articles By Alexa Meara MD

gout.podagra.jpg

Mitigating Immunogenicity When Using Uricase Therapies as ULT

ACR20 convergence highlights a shift in gout management and uric acid lowering therapy (ULT). The new biologics pegdriticase and pegloticase are associated with risk of immunogenicity and loss of biological effects.

Read Article
CNS.demyelinating.jpg

Best Imaging Techniques for non ANCA Vasculitis  

Large vessel vasculitis (LVV) and CNS vasculitis are rare subsets of vasculitis. The challenges related to these diseases are well known to the rheumatologists who treat around the world.

Read Article
Screen%20Shot%202018-11-01%20at%2010.14.03%20AM_0.png

Update on Checkpoint Inhibitor Safety

“Autoimmunity is the Achilles heel of onco-immunotherapy” per Dr. Leonard Calabrese, which leaves a dilemma for rheumatologists. Onco-immunotherapy induces immune dysregulation to allow patients to develop an immune response to their cancer cells. An unfortunate side effect for patients taking onco-immunotherapy is often autoimmune-like diseases referred to as immune adverse reactions (irAEs). Studies in France and the United States have shown that irAEs can be a good prognostic sign, suggesting these therapies are working. Rheumatology is faced with new problems as onco-immunotherapies may induce new chronic diseases in multiple different forms secondary to the treatment.

Read Article
×